MCA logo

PUBLIC PORTAL

MEDICALLY REVIEWED

Deucravacitinib (Sotyktu): First-In-Class, Allosteric Tyrosine Kinase 2 (Tyk2) Inhibitor For Adults With Moderate-To-Severe Plaque Psoriasis Approved

Psoriasis

Sign Up or Log In as a healthcare professional to read the full article.

Share via

Also worth reading

People also read: